Drug intelligence / Profile preview

BPI-003

Development stage: Preclinical
Lead developer: BeyondSpring
Modality: Small Molecules

Overview

BPI-003 is a novel small molecule inhibitor targeting IκB kinase (IKK), a protein kinase involved in the survival of certain tumor cells and the production of cytokines and growth factors that support tumor growth. By inhibiting IKK, BPI-003 disrupts pathways critical for tumor cell survival and proliferation. Preclinical studies have demonstrated promising activity, particularly in animal models of pancreatic cancer. The drug is being developed by BeyondSpring Pharmaceuticals as part of their oncology pipeline[1][2].

Targets

IKK complex

Beyond the preview

Go deeper on BPI-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI-003.

Explore the full profile